Skip to main content

Immunobiology and Immunotherapy

Section edited by Alessandra Cesano

The Immunobiology and Immunotherapy section aims to enrich the communication between basic biological and immunological sciences and the clinical investigation arena.

As immunology has evolved to be a central discipline connected to a wide range of therapeutic areas, the number and diversity of platform technologies has also increased, spanning small molecules, biologics, microbial vectors and cells. Such levels of activity require appropriate means to share new knowledge and to catalyze the development of the field. This section aims to provide such a platform and welcomes submissions across all disciplines, including inflammation, autoimmunity, transplantation, metabolic disorders.

The section was founded with the Society for Immunotherapy of Cancer (SITC) under the title "Tumor immunology and biological cancer therapy" and Pedro Romero was the founding Section Editor.

Page 9 of 9

  1. Adjuvant trastuzumab (Herceptin) treatment of breast cancer patients significantly improves their clinical outcome. Vaccination is an attractive alternative approach to provide HER-2/neu (Her2)-specific antibo...

    Authors: Håkan Norell, Isabel Poschke, Jehad Charo, Wei Z Wei, Courtney Erskine, Marie P Piechocki, Keith L Knutson, Jonas Bergh, Elisabet Lidbrink and Rolf Kiessling
    Citation: Journal of Translational Medicine 2010 8:53
  2. In preparation for potential clinical development of Ab-01, an antagonistic antibody directed against the IL21R, studies were undertaken to address translational medicine needs that fall into four categories: ...

    Authors: Maya Arai, Sadhana Jain, Amy A Weaver, Andrew A Hill, Yongjing Guo, Andrea G Bree, Michael F Smith Jr, Scott W Allen, Edward R LaVallie, Deborah Young, Laird Bloom, Karissa Adkins and Margot O'Toole
    Citation: Journal of Translational Medicine 2010 8:51
  3. Selective neutralization of the IL21/IL21R signaling pathway is a promising approach for the treatment of a variety of autoimmune diseases. Ab-01 is a human neutralizing anti-IL21R antibody. In order to ensure...

    Authors: Yongjing Guo, Andrew A Hill, Renee C Ramsey, Frederick W Immermann, Christopher Corcoran, Deborah Young, Edward R LaVallie, Mark Ryan, Theresa Bechard, Richard Pfeifer, Garvin Warner, Marcia Bologna, Laird Bloom and Margot O'Toole
    Citation: Journal of Translational Medicine 2010 8:50
  4. T-cell immunodeficiency is a common feature in cancer patients, which may relate to initiation and development of tumor. Based on our previous finding, to further characterize the immune status, T cell prolife...

    Authors: Yangqiu Li, Suxia Geng, Qingsong Yin, Shaohua Chen, Lijian Yang, Xiuli Wu, Bo Li, Xin Du, Christian A Schmidt and Grzegorz K Przybylski
    Citation: Journal of Translational Medicine 2010 8:47
  5. Combination immunotherapies can be effective against subcutaneous tumors in mice but the effect against orthotopic malignant disease is less well characterized. In particular, a combination of three agonist an...

    Authors: Jennifer A Westwood, Phillip K Darcy, Preethi Mayura Guru, Janelle Sharkey, Hollie J Pegram, Sally M Amos, Mark J Smyth and Michael H Kershaw
    Citation: Journal of Translational Medicine 2010 8:42
  6. Anti-IL-21R antibodies are potential therapeutics for the treatment of autoimmune diseases. This study evaluated correlations between the pharmacodynamic (PD) activity, pharmacokinetics, and anti-product antib...

    Authors: Yulia Vugmeyster, Scott Allen, Pamela Szklut, Andrea Bree, Mark Ryan, Margery Ma, Vikki Spaulding, Deborah Young, Heath Guay, Laird Bloom, Michael W Leach, Margot O'Toole and Karissa Adkins
    Citation: Journal of Translational Medicine 2010 8:41
  7. Several immunotherapeutic approaches rely on antigen-specific T-cells. Restrictions in the T-cell receptor (TCR) repertoire were reported as indicator of anti-tumor cytotoxic T-lymphocyte (CTL) response in var...

    Authors: Sebastian Ochsenreither, Alberto Fusi, Susanne Wojtke, Antonia Busse, Natascha C Nüssler, Eckhard Thiel, Ulrich Keilholz and Dirk Nagorsen
    Citation: Journal of Translational Medicine 2010 8:35
  8. Type-1 T cells are critical for effective anti-tumor immune responses. The recently discovered microRNAs (miRs) are a large family of small regulatory RNAs that control diverse aspects of cell function, includ...

    Authors: Kotaro Sasaki, Gary Kohanbash, Aki Hoji, Ryo Ueda, Heather A McDonald, Todd A Reinhart, Jeremy Martinson, Michael T Lotze, Francesco M Marincola, Ena Wang, Mitsugu Fujita and Hideho Okada
    Citation: Journal of Translational Medicine 2010 8:17
  9. Although an abundance of evidence has indicated that tumor-associated macrophages (TAMs) are associated with a favorable prognosis in patients with colon cancer, it is still unknown how TAMs exert a protective...

    Authors: Qiang Zhou, Rui-Qing Peng, Xiao-Jun Wu, Qing Xia, Jing-Hui Hou, Ya Ding, Qi-Ming Zhou, Xing Zhang, Zhi-Zhong Pang, De-Sen Wan, Yi-Xin Zeng and Xiao-Shi Zhang
    Citation: Journal of Translational Medicine 2010 8:13
  10. Glycoprotein-96, a non-polymorphic heat-shock protein, associates with intracellular peptides. Autologous tumor-derived heat shock protein-peptide complex 96 (HSPPC-96) can elicit potent tumor-specific T cell ...

    Authors: Omar Eton, Merrick I Ross, Mary Jo East, Paul F Mansfield, Nicholas Papadopoulos, Julie A Ellerhorst, Agop Y Bedikian and Jeffrey E Lee
    Citation: Journal of Translational Medicine 2010 8:9
  11. Due to the lack of specific tumor antigens, the majority of tested cancer vaccines for renal cell carcinoma (RCC) are based on tumor cell lysate. The identification of the von Hippel-Lindau (VHL) gene mutations i...

    Authors: Osama E Rahma, Ed Ashtar, Ramy Ibrahim, Antoun Toubaji, Barry Gause, Vincent E Herrin, W Marston Linehan, Seth M Steinberg, Frank Grollman, George Grimes, Sarah A Bernstein, Jay A Berzofsky and Samir N Khleif
    Citation: Journal of Translational Medicine 2010 8:8
  12. The conventional treatment protocol in high-intensity focused ultrasound (HIFU) therapy utilizes a dense-scan strategy to produce closely packed thermal lesions aiming at eradicating as much tumor mass as poss...

    Authors: Fang Liu, Zhenlin Hu, Lei Qiu, Chun Hui, Chao Li, Pei Zhong and Junping Zhang
    Citation: Journal of Translational Medicine 2010 8:7
  13. Efficacy of cancer vaccines may be limited due to immune escape mechanisms like loss or mutation of target antigens. Here, we analyzed 10 HLA-A2 positive patients with acute myeloid leukemia (AML) for loss or ...

    Authors: Antonia Busse, Anne Letsch, Carmen Scheibenbogen, Anika Nonnenmacher, Sebastian Ochsenreither, Eckhard Thiel and Ulrich Keilholz
    Citation: Journal of Translational Medicine 2010 8:5
  14. Dendritic cells (DCs) are often produced by granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleukin-4 (IL-4) stimulation of monocytes. To improve the effectiveness of DC adoptive immune cance...

    Authors: Ping Jin, Tae Hee Han, Jiaqiang Ren, Stefanie Saunders, Ena Wang, Francesco M Marincola and David F Stroncek
    Citation: Journal of Translational Medicine 2010 8:4
  15. Liposomal doxorubicin (Doxil) is a cytotoxic chemotherapy drug with a favorable hematologic toxicity profile. Its active drug, doxorubicin, has interesting immunomodulatory properties. Here, the effects of Dox...

    Authors: Ioannis Alagkiozidis, Andrea Facciabene, Carmine Carpenito, Fabian Benencia, Zdenka Jonak, Sarah Adams, Richard G Carroll, Phyllis A Gimotty, Rachel Hammond, Gwen-äel Danet-Desnoyers, Carl H June, Daniel J Powell Jr and George Coukos
    Citation: Journal of Translational Medicine 2009 7:104
  16. CD40 activation of antigen presenting cells (APC) such as dendritic cells (DC) and B cells plays an important role in immunological licensing of T cell immunity. Agonist CD40 antibodies have been previously sh...

    Authors: Erica L Carpenter, Rosemarie Mick, Jens Rüter and Robert H Vonderheide
    Citation: Journal of Translational Medicine 2009 7:93

Annual Journal Metrics